about
Parathyroid hormone pulsatility: physiological and clinical aspectsMeta-analysis on the effects of octreotide on tumor mass in acromegalyIncreased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis.Resistance to somatostatin analogs in acromegaly: an evolving concept?Growth hormone deficiency in the adult.Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.Octreotide for acromegaly treatment: a reappraisal.Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications.Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor?Growth hormone deficiency in treated acromegaly.Bone and Joint Disorders in Acromegaly.Pituitary diseases and bone.Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection.The Modern Criteria for Medical Management of Acromegaly.Growth hormone deficiency in treated acromegaly and active Cushing's syndrome.HIGH-DOSE AND HIGH-FREQUENCY LANREOTIDE AUTOGEL IN ACROMEGALY: A RANDOMIZED, MULTICENTER STUDY.Current and Emerging Aspects of Diabetes Mellitus in Acromegaly.Current and future medical treatments for patients with acromegaly.Acromegalic osteopathy.New medical therapies of acromegaly.Diabetes in Cushing Disease.MANAGEMENT OF ENDOCRINE DISEASE: RISK OF OVERTREATMENT OF PATIENTS WITH ADRENAL INSUFFICIENCY: CURRENT AND EMERGING ASPECTS.High prevalence of radiological vertebral fractures in HIV-infected males.Skeletal Fragility in Endogenous Hypercortisolism.Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency.High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome.Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency.High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas.Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis.Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis.Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles.Evolution of thyroid autoimmunity during iodine prophylaxis--the Sri Lankan experience.Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.Reevaluating thyrotropin receptor-induced mouse models of graves' disease and ophthalmopathy.Biological activity of activating thyrotrophin receptor mutants: modulation by iodide.Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.Vertebral fractures in males with prolactinoma.
P50
Q26798180-8949C38A-FD1E-4593-A6D2-34F18667CFEFQ28730120-72C2D9EB-0C3C-48B3-A4AE-39FD2D44D3CDQ34176625-2B7E8D20-ACF2-48A3-BF55-821A2EE1D786Q36428225-9DD2D44C-321E-441F-984F-6B24A4D4F1FCQ36640949-30D3278E-D01F-4931-81C5-99AA8FEAF2C1Q37384392-FDCA02C6-239D-40AC-A5C0-6C37C0FF2286Q37390169-99A073EB-45D1-4F7A-9EC3-5E78BBE380DDQ38152458-88897854-E736-4C2C-B63B-4CB2112395DEQ38178441-22628E91-1A25-43BB-B0EF-3782C22544D9Q38233686-BC8636E0-5CA2-4BD4-A4A6-E6E47865E336Q38239532-75A5A322-7D6D-464B-8390-88F9EC093BC9Q38272741-6241A518-62AB-4E99-B046-3064482E90AAQ38336931-8DDF14EE-AFF6-4201-9A57-8ADD084940CCQ38366921-CDB69A30-7478-495C-AD78-3F110E17C505Q38435884-FE607B2F-E87F-49E0-8000-62A9D3F2F5CFQ38759723-ACBE3B8F-1A92-4F43-A902-8CDAAC85F072Q38800726-A6E2FA17-AFAE-4A03-A96B-EBB585A52B7BQ38832298-C5505CD6-94ED-4036-863C-72006039ABF1Q38845414-B20B6862-39CF-47E4-ABB2-3255C2F61F82Q38847622-C9830C5C-FBB5-4DA8-84E6-4AE2C884360DQ38973343-73BFFDA2-DEB2-4BC9-A430-09186E1DCC6AQ38981882-9FD72A8F-AE32-433A-BBED-FA6D288C50A0Q39212408-9B046F03-8C59-4955-B5FB-A2DCBBC9CBE0Q39353087-128582AE-F6D4-4D9F-8D54-3F4E4DA4C847Q39530457-5235A232-3F49-4A33-BDF4-006BAB7D6FF8Q39746042-FA97C957-6713-42A6-8D73-1B19847344C4Q40470381-0C99B968-ED36-42E8-815D-FFBB6E97F43AQ41017909-AC3A6233-5CF1-43B0-BB79-50DDF7317AB3Q43105671-32D95299-2B16-4C2F-BCCB-0C57AA0131F0Q43903587-144F3F35-BC3D-4A0B-9A17-435E5C8BC844Q44125733-CFE0E607-529A-4F49-97CB-5CC71264F6C4Q44375660-22DB22BE-C184-42D4-92B7-E7949F70B7FAQ44472948-419EDB25-AAD1-4936-8B3F-BB25944835C7Q44481401-31359E3D-FC1A-4A15-9626-8D886B61DB02Q45045554-5B9B0578-CA76-472A-AA77-FEC0DE496B56Q45149782-185169E1-C588-482A-850C-49661C986089Q45251342-704B83E9-D9A1-4BD7-AF62-C0B63895FDE1Q45300463-D9D7568D-D497-4BD6-A111-3AAC24D35308Q45729932-300E60DB-F607-4C7B-A203-EA99ABB7CA7CQ45816493-F018208B-502F-40F1-B956-6C3FAFA1F0FE
P50
description
Forscher
@de
investigador
@es
onderzoeker
@nl
researcher
@en
ricercatore
@it
研究員
@ja
研究者
@zh
name
Gherardo Mazziotti
@en
Mazziotti G
@nl
type
label
Gherardo Mazziotti
@en
Mazziotti G
@nl
altLabel
Mazziotti G
@en
prefLabel
Gherardo Mazziotti
@en
Mazziotti G
@nl
P106
P31
P496
0000-0001-5458-701X